Ind-Swift Laboratories Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Trading below book value (P/B 1x)
- Virtually debt-free
Concerns
- Low capital efficiency (ROCE 4.9%)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
INDSWFTLAB · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 42.01% | 42.01% | 42.01% | 42.01% | 42.01% | 40.94% |
| FII | 0.31% | 0.26% | 1.27% | 0.65% | 0.46% | 3.07% |
| DII | 18.73% | 8.03% | 0.94% | 0.94% | 0.94% | 0.91% |
| Public | 38.96% | 49.72% | 55.81% | 56.41% | 56.61% | 55.08% |
Latest News
All newsInd-Swift Laboratories issues newspaper publication notice
*Ind-Swift Laboratories issues newspaper publication notice* as part of regulatory compliance. The company informed the exchange about the publication, a routine corporate filing requirement. No financial figures or strategic developments were disclosed. Such notices are typically procedural and do not impact operations. 📊 *STOCKS:* $INDSWFTLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Ind-Swift Labs announces preferential issue outcome
*Ind-Swift Labs announces outcome of preferential issue committee meeting.* The decision follows a meeting held on **September 4, 2026**, as mandated under **Regulation 30** of SEBI Listing Regulations. No financial figures or strategic changes were disclosed. The update is procedural in nature. 📊 *STOCKS:* $INDSWFTLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #PreferentialIssue
Ind-Swift Laboratories issues corporate press release
*Ind-Swift Laboratories issues corporate press release.* The company filed a press release with the NSE, though details are not disclosed in the headline. Investors are advised to review the attached PDF for complete information. No financial figures or material events are highlighted in the summary. 📊 *STOCKS:* INDSWFTLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
About Ind-Swift Laboratories Limited
Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals[1]
HealthcarePharmaceuticals & Biotechnology